Skip to main content
×
×
Home

Systematic meta-review of depot antipsychotic drugs for people with schizophrenia

  • Clive E. Adams (a1), Mark K. P. Fenton (a1), Seema Quraishi (a2) and Anthony S. David (a2)
Abstract
Background

Long-acting depot antipsychotic medication is a widely used treatment for schizophrenia.

Aims

To synthesise relevant systematic Cochrane reviews.

Method

The Cochrane Database was searched and summary data were extracted from randomised controlled clinical trials of depots.

Results

Standard dose depot v. placebo resulted in significantly less relapse but more movement disorders. Those on depots (v. oral drugs) showed more global change on one outcome measure; relapse and adverse effects showed no difference. Comparisons showed no convincing advantages for one depot over another.

Conclusions

Depot antipsychotics are safe and effective. They may confer a small benefit over oral drugs on global outcome. Those for whom depots are most indicated may not be represented. Large studies are required to discern differences in relapse rates and long-term adverse effects, and data on satisfaction, quality of life and economics.

  • View HTML
    • Send article to Kindle

      To send this article to your Kindle, first ensure no-reply@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about sending to your Kindle. Find out more about sending to your Kindle.

      Note you can select to send to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be sent to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

      Find out more about the Kindle Personal Document Service.

      Systematic meta-review of depot antipsychotic drugs for people with schizophrenia
      Available formats
      ×
      Send article to Dropbox

      To send this article to your Dropbox account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Dropbox.

      Systematic meta-review of depot antipsychotic drugs for people with schizophrenia
      Available formats
      ×
      Send article to Google Drive

      To send this article to your Google Drive account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Google Drive.

      Systematic meta-review of depot antipsychotic drugs for people with schizophrenia
      Available formats
      ×
Copyright
Corresponding author
Professor Anthony S. David, Institute of Psychiatry & GKT School of Medicine, Denmark Hill, London SE5 8AF, UK. Tel: 020 7848 0138; Fax: 020 7848 0572; e-mail: a.david@iop.kcl.ac.uk
Footnotes
Hide All

See pp. 300–307, this issue.

Declaration of interest

Funded by the NHS Health Technology Assessment programme. A. S. D. is participating in a trial funded by Janssen-Cilag and has been an advisor for them. The Cochrane Schizophrenia Group has received funding from pharmaceutical companies, the NHS and Department of Health.

Footnotes
References
Hide All
Adams, C. E. & Eisenbruch, M. (2000) Depot fluphenazine for schizophrenia. Cochrane Library, issue 3. Oxford: Update Software
Åsberg, M., Montgomery, S., Perris, C., et al (1978) The comprehensive psychopathological scale. Acta Psychiatrica Scandinavica Supplementum, 271, 527.
Barnes, T. R. & Curson, D. A. (1994) Long term depot antipsychotics. A risk–benefit assessment. Drug Safety, 10, 464479.
Begg, C., Cho, M., Eastwood, S., et al (1996) Improving the quality of reporting of randomised controlled trials. The CONSORT statement. Journal of the American Medical Association, 276, 637639.
Boissel, J. P., Cucherat, M., Li, W., et al (1999) The problem of therapeutic efficacy indices. 3. Comparison of the indices and their use. Thérapie, 54, 405411.
Bordeleau, J. M., Albert, J. M., Killer, J., et al (1967) Médication antiparkinsonienne et bilan extrapyramidal. Étude du trihexyphenidyl. Canadian Psychiatric Association Journal, 12, 585595.
British Medical Association & Royal Pharmaceutical Society of Great Britain (1999) British National Formulary. London & Wellingford: BMJ Books & Pharmaceutical Press.
Chalmers, T. C., Celano, P., Sacks, H. S., et al (1983) Bias in treatment assignment in controlled clinical trials. New England Journal of Medicine, 309, 13581361.
Coutinho, E., Fenton, M. & Quraishi, S. (2000) Zuclopenthixol decanoate for schizophrenia and other serious mental illnesses. Cochrane Library, issue 2. Oxford: Update Software
Davis, J. M. & Andriukaitis, S. (1986) The natural course of schizophrenia and effective maintenance drug treatment. Journal of Clinical Psychopharmacology, 6, 2S10S.
Davis, J. M., Matalon, L., Watanabe, M. D., et al (1994) Depot antipsychotic drugs. Place in therapy. Drugs, 47, 741773.
Fenton, W. S., Blyler, C. R. & Heinssen, R. K. (1997) Determinants of medication compliance in schizophrenia: empirical and clinical findings. Schizophrenia Bulletin, 23, 637651.
Foster, K., Meltzer, H., Gill, B., et al (1996) Adults with a psychotic disorder living in the community. OPCS Surveys of Psychiatric Morbidity in Great Britain, Report 8. London: HMSO
Gerlach, J. (1995) Depot neuroleptics in relapse prevention: advantages and disadvantages. International Clinical Psychopharmacology, 9 (suppl. 5), 1720.
Gilbody, S. M. & Song, F. (2000) Publication bias and the integrity of psychiatry research. Psychological Medicine, 30, 253258.
Glazer, W. M. & Kane, J. M. (1992) Depot neuroleptic therapy: an underutilized treatment option. Journal of Clinical Psychiatry, 53, 426433.
Guy, W. (1976) ECDEU Assessment Manual for Psychopharmacology. Revised DHEW Pub. (ADM). Rockville, MD: National Institute for Mental Health
Hamilton, M. (1960) A rating scale for depression. Journal of Neurology, Neurosurgery and Psychiatry, 23, 5662.
Hirsch, S. R., Gaind, R., Rohde, P. D., et al (1973) Outpatient maintenance of chronic schizophrenic patients with long-acting fluphenazine: double-blind placebo controlled trial. British Medical Journal, i, 633637.
Honigfeld, G., Gillis, R. D. & Klett, C. J. (1962) NOSIE-30: a treatment sensitive ward behavior scale. Psychological Reports, 10, 799812.
Hotopf, M., Churchill, R. & Lewis, G. (1999) Pragmatic randomised controlled trials in psychiatry. British Journal of Psychiatry, 175, 217223.
Jadad, A. R., Cook, D. J., Jones, A., et al (1998) Methodology and reports of systematic reviews and meta-analyses: a comparison of Cochrane reviews with articles published in paper-based journals. Journal of the American Medical Association, 280, 278280.
Johnson, D. A. (1984) Observations on the use of long-acting depot neuroleptic injections in the maintenance therapy of schizophrenia. Journal of Clinical Psychiatry, 45, 1321.
Kane, J. M., Aguglia, E., Altamura, A. C., et al (1998) Guidelines for depot antipsychotic treatment in schizophrenia. European Neuropsychopharmacology Consensus Conference in Siena, Italy. European Neuropsychopharmacology, 8, 5566.
Kemp, R. A. & David, A. S. (1997) Insight and compliance. In Treatment Compliance and the Therapeutic Alliance (ed. Blackwell, B.), pp. 6184. Newark, NJ: Harwood Academic.
Krawiecka, M., Goldberg, D. & Vaughn, M. (1977) Standardised psychiatric assessment scale for chronic psychiatric patients. Acta Psychiatrica Scandinavica, 36, 2531.
Lingjaerde, O., Ahlfors, U. G., Bech, P., et al (1987) The UKU side effects rating scale. Acta Psychiatrica Scandinavica, 76 (suppl. 334), 1100.
Montgomery, S. A., Taylor, P. & Montgomery, D. (1978) Development of a schizophrenia scale sensitive to change. Neuropharmacology, 78, 10611062.
Overall, J. E. & Gorham, D. R. (1962) The Brief Psychiatric Rating Scale. Psychological Reports, 10, 799812.
Quraishi, S. & David, A. (2000) Depot flupenthixol decanoate for schizophrenia or other similar psychotic disorders. Cochrane Library, issue 3. Oxford: Update Software
Quraishi, S. & David, A. (2000) Depot fluspirilene for schizophrenia. Cochrane Library, issue 3. Oxford: Update Software
Quraishi, S. & David, A. (2000) Depot haloperidol decanoate for schizophrenia. Cochrane Library, issue 3. Oxford: Update Software
Quraishi, S. & David, A. (2000) Depot perphenazine decanoate and enanthate for schizophrenia. Cochrane Library, issue 3. Oxford: Update Software
Quraishi, S. & David, A. (2000) Depot pipothiazine palmitate and undecylenate for schizophrenia. Cochrane Library, issue 3. Oxford: Update Software
Quraishi, S. & David, A. & Adams, C. E. (2000) Depot bromperidol decanoate for schizophrenia. Cochrane Library, issue 3. Oxford: Update Software
Schulz, K. F., Chalmers, I., Hayes, R. J., et al (1995) Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials. Journal of the American Medical Association, 273, 408412.
Simpson, G. M. (1984) A brief history of depot neuroleptics. Journal of Clinical Psychiatry, 45, 34.
Simpson, M. & Angus, J. W. (1970) A rating scale for extrapyramidal side effects. Acta Psychiatrica Scandinavica, 212, 1119.
Thornley, B. & Adams, C. (1998) Content and quality of 2000 controlled trials in schizophrenia over 50 years. British Medical Journal, 317, 11811184.
Walburn, J., Gray, R., Gournay, K., et al (2001) Systematic review of patient and nurse attitudes to depot antipsychotic medication. British Journal of Psychiatry, 179, 300307.
Weiden, P. J. & Olfson, M. (1995) Cost of relapse in schizophrenia. Schizophrenia Bulletin, 21, 419429.
Wing, J. K. (1961) A simple and reliable subclassification of chronic schizophrenia. Journal of Mental Science, 107, 862876.
Recommend this journal

Email your librarian or administrator to recommend adding this journal to your organisation's collection.

The British Journal of Psychiatry
  • ISSN: 0007-1250
  • EISSN: 1472-1465
  • URL: /core/journals/the-british-journal-of-psychiatry
Please enter your name
Please enter a valid email address
Who would you like to send this to? *
×

Metrics

Altmetric attention score

Full text views

Total number of HTML views: 0
Total number of PDF views: 0 *
Loading metrics...

Abstract views

Total abstract views: 0 *
Loading metrics...

* Views captured on Cambridge Core between <date>. This data will be updated every 24 hours.

Usage data cannot currently be displayed

Systematic meta-review of depot antipsychotic drugs for people with schizophrenia

  • Clive E. Adams (a1), Mark K. P. Fenton (a1), Seema Quraishi (a2) and Anthony S. David (a2)
Submit a response

eLetters

No eLetters have been published for this article.

×

Reply to: Submit a response


Your details


Conflicting interests

Do you have any conflicting interests? *